Blair Jackson, the newly appointed CEO of Alkermes, has outlined a strategic vision for the next 12 months that he deems critical for the company’s future. As Alkermes positions itself to enter the burgeoning orexin market, which analysts project could be worth billions, Jackson emphasizes the urgency of this transition.
This move comes at a time when major competitors like Lilly and Takeda are also vying for dominance in the treatment of narcolepsy and related disorders. The orexin market represents not only a significant revenue opportunity but also a chance for Alkermes to differentiate itself in a crowded therapeutic landscape.
For pharma B2B professionals, this development signals a potential shift in market dynamics, as Alkermes seeks to leverage its innovative capabilities to capture market share. The success of this strategy could reshape competitive relationships within the sector, highlighting the importance of agility and foresight in pharmaceutical development.
Get started today with Solo access →
